BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update
BrainStorm to request Type A meeting with FDA to facilitate NurOwn’s advancement following receipt of a refusal to file letter regarding the company’s new Biologics License Application Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK, Nov. 14, 2022 /PRNewswire/ –…
Comments Off on BrainStorm Cell Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Corporate Update